Loading...
Market
Will the acquisition of Novartis' Molecular Imaging Business by Siemens Healthineers receive regulatory approval by March 31, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Announcements from regulatory bodies such as the European Commission or the U.S. Federal Trade Commission (FTC)
Story
Siemens Healthineers to Acquire Novartis' Molecular Imaging Business in $224 Million Deal
Aug 26, 2024, 12:36 PM
Siemens Healthineers has agreed to acquire a part of Novartis' business specializing in radioactive chemicals used for cancer scans. The $224 million deal involves the molecular imaging business for Fluorine-18 positron emission tomography (PET) scans. This acquisition is expected to further boost Siemens Healthineers' healthcare operations. Novartis confirmed receiving a binding offer from Siemens Healthineers for this acquisition.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
